Literature DB >> 35114676

Primary non-function and early allograft dysfunction after liver transplantation.

Łukasz Masior, Michał Grąt.   

Abstract

BACKGROUND: Despite continuous progress in the field of liver transplantation, considerable proportion of patients still suffer from the post-operative graft dysfunction. Clinically it presents as early graft dysfunction (EAD) and its more severe form defined as primary non-function (PNF). Post-transplant liver dysfunction translates into significantly worse treatment outcomes.
SUMMARY: Both entities are multifactorial, with donor (graft), recipient and procedure related factors playing the key roles. Ischemia reperfusion injury (IRI) is a major driver of their development. So far, various non-invasive (pharmacological) and invasive strategies have been tested to mitigate its negative effects. This article presents current approach to diagnosis, prediction and management of EAD and PNF. Key messages: Different pharmacological interventions may be considered to improve graft function after liver transplantation. Machine perfusion seems to be the most effective method at the moment. S. Karger AG, Basel.

Entities:  

Year:  2022        PMID: 35114676     DOI: 10.1159/000522052

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  2 in total

1.  Developing a new nomogram to predict early allograft dysfunction after liver transplantation: a nudge in the right direction.

Authors:  Gang Xu; Chen-Hao Jiang; Tao Lv; Jiu-Lin Song; Yong-Jie Zhou; Jian Yang; Li Jiang; Lyu-Nan Yan; Kui Luo; Jia-Yin Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

2.  Itaconic acid facilitates inflammation abatement and alleviates liver ischemia-reperfusion injury by inhibiting NF-κB/NLRP3/caspase-1 inflammasome axis.

Authors:  Ensi Ma; Hao Xing; Jiahao Pei; Quanbao Zhang; Ruidong Li; Conghuan Shen; Yifeng Tao; Jianhua Li; Zhenyu Ma; Jing Zhao; Zhengxin Wang
Journal:  Ann Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.